Back to results
US 9,265,815 B2Granted
Tolerogenic synthetic nanocarriers
AssigneeSelecta Biosciences, Inc.
InventorsChristopher Fraser, Grayson B. Lipford, Christopher J. Roy, Roberto A. Maldonado
Life of this patent
Estimating the term…
Abstract
This invention relates, at least in part, to compositions comprising synthetic nanocarriers and immunosuppressants that result in immune suppressive effects. Such compositions can further comprise antigen and provide antigen-specific tolerogenic immune responses.
Claims10
A composition comprising:
- (i) a first population of polymeric synthetic nanocarriers coupled to rapamycin, and
- (ii) a second population of polymeric synthetic nanocarriers coupled to an antigen-presenting cell (APC) presentable antigen,
- wherein at least 75% of the polymeric synthetic nanocarriers of the first population of synthetic nanocarriers have a minimum dimension, obtained using dynamic light scattering, that is greater than 110 nm and a maximum dimension, obtained using dynamic light scattering, that is equal to or less than 500 nm,
- wherein the load of the rapamycin on average across the first population of synthetic nanocarriers is at least 2% but no more than 25% (weight/weight), and
- wherein the load of the APC presentable antigen on average across the second population of polymeric synthetic nanocarriers is between 1% and 10% weight/weight.
2 more elements
Dependencies are inferred from the claim text.